SPOTLIGHT -
-
What We’re Reading: Sickle Cell Disease and Exa-cel Gene Therapy
New Lung Cancer Drug Augtyro is Now Available
Augtyro, approved last month, launched with a month wholesale acquisition $29,000 for patients with ROS1-positive non-small cell lung cancer.
Study Questions Whether the High Price of Ocrevus is Warranted
Researchers suggest a head-to-head comparative effectiveness study of Ocrevus and Rituxan/biosimilars in patients with multiple sclerosis is needed for payers to negotiate prices for these therapies.
FDA Approves Fabhalta, an Oral Treatment for Rare Blood Disorder
Fabhalta was approved to treat patients with paroxysmal nocturnal hemoglobinuria and will have a wholesale acquisition cost of $550,000 per year.
CarelonRx Will Launch Digital Pharmacy in 2024
CarelonRx says it will be able provide optimal support for members because, as a PBM, it as able to communicate directly with members’ providers.
Express Scripts and Cigna Add Zepbound to Formularies
Zepbound, which was approved last month to treat obesity, is now available in U.S. pharmacies.
